金斯瑞生物科技(01548.HK):主要股東向控股股東收購股份 控股股東承諾一年內不減持股份
格隆匯12月13日丨金斯瑞生物科技(01548.HK)發佈公吿,公司已獲公司控股股東Genscript Corporation(“GS Corp”)吿知,2023年12月12日,GS Corp與GNS II Holdings Limited(“買方”)就轉讓公司股份訂立協議,據此,GS Corp已同意以每股股份18.20港元出售而買方已同意購買857.8萬股股份(佔於本公吿日期的現有已發行股本約0.40%)。購買股份的總對價為約1.56億港元(相當於約1999.74萬美元)。
就收購事項而言,買方已同意在代理期內向GS Corp授予(其中包括)其作為買方所購股份的代理人根據委託書條款進行投票及簽署公司書面決議的權利。此外,GS Corp已向買方承諾,GS Corp於完成日期1年內不會減持公司股份。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.